Karsten Keller1, Kathrin Stelzer2, Mir Abolfazl Ostad3, Felix Post4. 1. Center for Thrombosis and Hemostasis, University Medical Center Mainz (Johannes Gutenberg-University Mainz), Mainz, Germany; Center for Cardiology, Department of Cardiology I, University Medical Center Mainz (Johannes Gutenberg-University Mainz), Mainz, Germany; Team Doctor of the German Bundesliga Club, 1. FSV Mainz 05 in the Soccer Season 2014/2015, Mainz, Germany. Electronic address: Karsten.Keller@unimedizin-mainz.de. 2. Center for Cardiology, Department of Cardiology I, University Medical Center Mainz (Johannes Gutenberg-University Mainz), Mainz, Germany; Team Doctor of the German Bundesliga Club, 1. FSV Mainz 05 in the Soccer Season 2014/2015, Mainz, Germany. 3. Center for Cardiology, Department of Cardiology I, University Medical Center Mainz (Johannes Gutenberg-University Mainz), Mainz, Germany. 4. Department of Internal Medicine and Cardiology, Catholic Clinic Koblenz, Koblenz, Germany; Team Doctor of the German Bundesliga Club, 1. FSV Mainz 05 in the Soccer Season 2014/2015, Mainz, Germany.
Abstract
PURPOSE: Arterial hypertension (aHT) is the leading risk factor for morbidity and mortality worldwide. Blood pressure (BP) deviation at rest is well defined and accompanies risk for cardiovascular events and cardiovascular mortality. A growing body of evidence emphasises that an exaggerated blood pressure response (EBPR) in cardiopulmonary exercise testing (CPET) could help to identify seemingly cardiovascular healthy and normotensive subjects, who have an increased risk of developing aHT and cardiovascular events in the future. MATERIALS AND METHODS: The PubMed online database was searched for published studies reporting exercise-related BP and both the risk of aHT and cardiovascular events in the future. RESULTS: We identified 18 original studies about EBPR in CPET, which included a total of 35,151 normotensive individuals for prediction of new onset of aHT in the future and 11 original studies with 43,012 enrolled subjects with the endpoint of cardiovascular events in the future. Although an EBPR under CPET is not well defined, a large number of studies emphasise that EBPR in CPET is associated with both new-onset aHT and cardiovascular events in the future. CONCLUSIONS: A growing number of studies support the hypothesis that EBPR in CPET may be a diagnostic tool to identify subjects with an elevated risk of developing aHT and cardiovascular events in the future.
PURPOSE: Arterial hypertension (aHT) is the leading risk factor for morbidity and mortality worldwide. Blood pressure (BP) deviation at rest is well defined and accompanies risk for cardiovascular events and cardiovascular mortality. A growing body of evidence emphasises that an exaggerated blood pressure response (EBPR) in cardiopulmonary exercise testing (CPET) could help to identify seemingly cardiovascular healthy and normotensive subjects, who have an increased risk of developing aHT and cardiovascular events in the future. MATERIALS AND METHODS: The PubMed online database was searched for published studies reporting exercise-related BP and both the risk of aHT and cardiovascular events in the future. RESULTS: We identified 18 original studies about EBPR in CPET, which included a total of 35,151 normotensive individuals for prediction of new onset of aHT in the future and 11 original studies with 43,012 enrolled subjects with the endpoint of cardiovascular events in the future. Although an EBPR under CPET is not well defined, a large number of studies emphasise that EBPR in CPET is associated with both new-onset aHT and cardiovascular events in the future. CONCLUSIONS: A growing number of studies support the hypothesis that EBPR in CPET may be a diagnostic tool to identify subjects with an elevated risk of developing aHT and cardiovascular events in the future.
Authors: Pascal Bauer; Lutz Kraushaar; Sophie Hoelscher; Rebecca Weber; Ebru Akdogan; Stanislav Keranov; Oliver Dörr; Holger Nef; Christian W Hamm; Astrid Most Journal: Sports Med Int Open Date: 2021-04-19
Authors: Kristofer Hedman; Thomas Lindow; Nicholas Cauwenberghs; Anna Carlén; Viktor Elmberg; Lars Brudin; Magnus Ekström Journal: J Hypertens Date: 2022-02-01 Impact factor: 4.776
Authors: Akothirene C Dutra-Marques; Sara Rodrigues; Felipe X Cepeda; Edgar Toschi-Dias; Eduardo Rondon; Jefferson C Carvalho; Maria Janieire N N Alves; Ana Maria F W Braga; Maria Urbana P B Rondon; Ivani C Trombetta Journal: Front Neurosci Date: 2021-06-09 Impact factor: 4.677
Authors: Kevin F Boreskie; D Scott Kehler; Eduardo C Costa; Pedro C Cortez; Ivan Berkowitz; Naomi C Hamm; Teri L Moffatt; Andrew N Stammers; Dustin E Kimber; Brett M Hiebert; David E Kent; Denise E Cornish; Heather Blewett; Thang Nguyen; Rakesh C Arora; Shaelyn M Strachan; Brittany N Semenchuk; Jacqueline L Hay; Jay N Cohn; Todd A Duhamel Journal: BMJ Open Date: 2017-11-03 Impact factor: 2.692